Literature DB >> 14691637

Expression profiling of favorable and unfavorable neuroblastomas.

Eiso Hiyama1, Keiko Hiyama, Hiroaki Yamaoka, Taijiro Sueda, C Patrik Reynolds, Takashi Yokoyama.   

Abstract

Neuroblastomas show remarkable biological heterogeneity, resulting in favorable or unfavorable outcomes. To survey the differences in gene expression profiles between favorable and unfavorable neuroblastomas, we analyzed ten favorable neuroblastoma samples from patients whose tumors consequently regressed or matured and ten unfavorable tumor samples from patients who consequently died of disease using the microarray technique. In each sample, total RNA was labeled with Cy3 or Cy5 in reverse-trancriptase reaction and hybridized with our original microarray prepared with a cDNA library of human fetal brain. Microarray analysis revealed that 43 genes, including MYCN, hTERT, NME1 and cell cycle regulatory protein-coding genes, were highly expressed in unfavorable neuroblastomas, while another 80 genes were detected as highly expressed in favorable tumors, including neuronal differentiating genes and apoptotic inducing genes. Among favorable neuroblastoma samples, highly expressing genes in regressing tumors were different from those in maturing tumors. Expression profiling data revealed the existence of up-regulated and down-regulated gene clusters in favorable and unfavorable tumors. This cluster analysis is a powerful procedure to distinguish unfavorable tumors from favorable tumors as well as regressing tumors from maturing tumors among favorable tumors. The information obtained from expression profiling would clarify the key genes for cell growth, regression or maturation of neuroblastoma cells, and these genes will become diagnostic and therapeutic targets in human neuroblastoma in the future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691637     DOI: 10.1007/s00383-003-1077-3

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  13 in total

1.  Assessing reliability of gene clusters from gene expression data.

Authors:  K Zhang; H Zhao
Journal:  Funct Integr Genomics       Date:  2000-11       Impact factor: 3.410

2.  TGF-beta1 increases tyrosine hydroxylase expression by a mechanism blocked by BMP-2 in human neuroblastoma SH-SY5Y cells.

Authors:  Cristina Gómez-Santos; Santiago Ambrosio; Francesc Ventura; Isidre Ferrer; Julia Reiriz
Journal:  Brain Res       Date:  2002-12-20       Impact factor: 3.252

3.  Developmental gene expression of sympathetic nervous system tumors reflects their histogenesis.

Authors:  J C Hoehner; F Hedborg; L Eriksson; B Sandstedt; L Grimelius; L Olsen; S Påhlman
Journal:  Lab Invest       Date:  1998-01       Impact factor: 5.662

4.  Quantitative monitoring of gene expression patterns with a complementary DNA microarray.

Authors:  M Schena; D Shalon; R W Davis; P O Brown
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

5.  The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.

Authors:  Marc B Godfried; Monique Veenstra; Peter v Sluis; Kathy Boon; Ronald v Asperen; Marie Christien Hermus; Barbara D C v Schaik; Tom P A Voûte; Manfred Schwab; Rogier Versteeg; Huib N Caron
Journal:  Oncogene       Date:  2002-03-27       Impact factor: 9.867

Review 6.  Genetic parameters of neuroblastomas.

Authors:  Frank Westermann; Manfred Schwab
Journal:  Cancer Lett       Date:  2002-10-28       Impact factor: 8.679

7.  Cell adhesion molecules and intermediate filaments on embryonal childhood tumors.

Authors:  S Glüer; M Zense; D von Schweinitz
Journal:  Pathol Res Pract       Date:  1998       Impact factor: 3.250

8.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.

Authors:  H Shimada; J Chatten; W A Newton; N Sachs; A B Hamoudi; T Chiba; H B Marsden; K Misugi
Journal:  J Natl Cancer Inst       Date:  1984-08       Impact factor: 13.506

Review 9.  International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review.

Authors:  B H Kushner; N K Cheung; M P LaQuaglia; P F Ambros; I M Ambros; M A Bonilla; M Ladanyi; W L Gerald
Journal:  J Clin Oncol       Date:  1996-07       Impact factor: 44.544

10.  Correlating telomerase activity levels with human neuroblastoma outcomes.

Authors:  E Hiyama; K Hiyama; T Yokoyama; Y Matsuura; M A Piatyszek; J W Shay
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

View more
  11 in total

1.  High genomic instability predicts survival in metastatic high-risk neuroblastoma.

Authors:  Sara Stigliani; Simona Coco; Stefano Moretti; Andrè Oberthuer; Mattias Fischer; Jessica Theissen; Fabio Gallo; Alberto Garavent; Frank Berthold; Stefano Bonassi; Gian Paolo Tonini; Paola Scaruffi
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

Review 2.  Cell Adhesion Molecules in Neuroblastoma: Complex Roles, Therapeutic Potential.

Authors:  Briana E Heinly; Christa N Grant
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

3.  Evaluation of genes identified by microarray analysis in favorable neuroblastoma.

Authors:  Naomi Kamei; Keiko Hiyama; Hiroaki Yamaoka; Arata Kamimatsuse; Yoshiyuki Onitake; Taijiro Sueda; Eiso Hiyama
Journal:  Pediatr Surg Int       Date:  2009-11       Impact factor: 1.827

4.  Heterogeneous subgroups in human neuroblastoma for clinically relevant risk stratification.

Authors:  Eiso Hiyama; Hiroaki Yamaoka; Satoshi Kondo; Akihiro Yoneda; Tatsuro Tajiri; Masahiro Fukuzawa; Masahiko Sugiyama; Yutaka Hayashi; Fumiaki Sasaki; Megu Ohtaki
Journal:  Pediatr Surg Int       Date:  2007-08-16       Impact factor: 1.827

5.  Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.

Authors:  Sara Stigliani; Michela Croce; Fabio Morandi; Paola Scaruffi; Valentina Rigo; Barbara Carlini; Carla Manzitti; Anna Rita Gigliotti; Gian Paolo Tonini; Vito Pistoia; Silvano Ferrini; Maria Valeria Corrias
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

6.  Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation.

Authors:  Laurent Sakka; Nathalie Delétage; Maryse Chalus; Youssef Aissouni; Valérie Sylvain-Vidal; Stéphane Gobron; Guillaume Coll
Journal:  Oncotarget       Date:  2017-06-27

7.  Integrative analysis based on survival associated co-expression gene modules for predicting Neuroblastoma patients' survival time.

Authors:  Yatong Han; Xiufen Ye; Jun Cheng; Siyuan Zhang; Weixing Feng; Zhi Han; Jie Zhang; Kun Huang
Journal:  Biol Direct       Date:  2019-02-13       Impact factor: 4.540

8.  CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours.

Authors:  Francisco M Vega; Ana Colmenero-Repiso; María A Gómez-Muñoz; Ismael Rodríguez-Prieto; Diana Aguilar-Morante; Gema Ramírez; Catalina Márquez; Rosa Cabello; Ricardo Pardal
Journal:  EBioMedicine       Date:  2019-11-02       Impact factor: 8.143

9.  Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes.

Authors:  Kaisa Thorell; Annika Bergman; Helena Carén; Staffan Nilsson; Per Kogner; Tommy Martinsson; Frida Abel
Journal:  BMC Med Genomics       Date:  2009-08-17       Impact factor: 3.063

10.  Integrative analysis of neuroblastoma and pheochromocytoma genomics data.

Authors:  Peter M Szabó; Miklós Pintér; Diana Rita Szabó; Adrienn Zsippai; Attila Patócs; András Falus; Károly Rácz; Peter Igaz
Journal:  BMC Med Genomics       Date:  2012-10-29       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.